nci_id,cluster_id,tsne_x,tsne_y,codes_text
NCI-2009-00817,4,-12.696568489074707,-2.5754833221435547,Human immunodeficiency virus (HIV) negative
NCI-2011-00312,0,5.053690433502197,8.348408699035645,Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
NCI-2011-00878,0,-9.185900688171387,6.779380798339844,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients

"
NCI-2011-01915,0,6.273831367492676,6.231972694396973,"Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study"
NCI-2011-01973,0,-8.485798835754395,2.009936571121216,"Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)"
NCI-2011-01974,0,-8.19375228881836,5.324880599975586,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients"
NCI-2011-01987,4,8.986861228942871,3.2840301990509033,Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
NCI-2011-01992,4,-5.325077056884766,0.41472327709198,"*B21Patients with known human immunodeficiency virus (HIV) infection are excluded                          

*No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies"
NCI-2011-02034,0,0.39793887734413147,10.298637390136719,"Patients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk"
NCI-2011-02500,3,1.3555563688278198,-1.832167625427246,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible"
NCI-2011-02515,4,-8.097931861877441,10.121696472167969,"Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring antiretroviral therapy, "
NCI-2011-02539,0,6.573894023895264,-6.595823287963867,Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2011-02592,4,1.2944411039352417,1.2781273126602173,"Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study"
NCI-2011-02673,0,4.850718021392822,9.222810745239258,Patients must not be known to be human immunodeficiency virus (HIV)-positive
NCI-2011-02674,1,-8.18733024597168,5.332120418548584,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients"
NCI-2012-00680,0,-7.111593246459961,3.097174882888794,PROCUREMENT: Patients with active human immunodeficiency virus (HIV) positive at time of procurement (can be pending at the time of blood draw)
NCI-2012-00860,0,8.515836715698242,-3.0479395389556885,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment
NCI-2012-00864,4,4.281697750091553,9.762874603271484,"Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible"
NCI-2012-01040,4,-11.062090873718262,3.8034613132476807,"Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator"
NCI-2012-01695,4,-13.862431526184082,8.194755554199219,"All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load > 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine [AZT]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment          

*HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL


* WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load"
NCI-2012-01712,4,4.3775129318237305,-0.7025667428970337,"Exclusion:

HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible


Inclusion:
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ cluster of differentiation 4 (CD4)+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions"
NCI-2012-01995,0,7.091732501983643,6.346423149108887,Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease
NCI-2012-01998,3,5.468653202056885,4.544806480407715,"Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:

* Cluster of differentiation (CD)4 cells >= 500/mm^3

* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART

* No zidovudine or stavudine as part of cART

* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study"
NCI-2012-02009,0,8.018193244934082,-4.863396167755127,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible
NCI-2012-02057,0,11.505751609802246,-6.773062229156494,Use of combination anti-retroviral therapy for human immunodeficiency virus (HIV)
NCI-2012-02608,0,-10.859307289123535,2.3616995811462402,"STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:

* Cluster of differentiation (CD)4 cell count >= 350/mm^3

* No history of acquired immune deficiency syndrome (AIDS)-related illness

* Not currently prescribed zidovudine or stavudine"
NCI-2012-02767,0,5.9202351570129395,6.774339199066162,Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy
NCI-2012-02875,0,-13.654579162597656,-1.390559196472168,"Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)"
NCI-2012-03124,0,7.986170291900635,-7.12912130355835,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-00046,4,0.3059844970703125,-4.507761478424072,"Participants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvement

Participants must discontinue use of the following agents within 7 days prior to therapy

* Strong CYP3A4 inhibitors that treat HIV

* If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy

HIV positive; documentation of HIV-1 infection by means of any one of the following:

* Documentation of HIV diagnosis in the medical record by a licensed health care provider;

* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;

* HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;

* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay
Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible
* NOTE: A Ã¢â¬ÅlicensedÃ¢â¬Â assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies

Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible "
NCI-2013-00370,0,-9.268887519836426,6.069780349731445,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol

"
NCI-2013-00500,0,-8.19728946685791,5.321386814117432,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients"
NCI-2013-00716,0,-0.331832617521286,3.3984873294830322,"Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to: active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, ... that would limit compliance with study requirements"
NCI-2013-00737,0,-8.190654754638672,5.3279876708984375,"Severe, active co-morbidity, defined as follows:


* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients"
NCI-2013-00739,0,-2.735102653503418,2.9676923751831055,"Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded"
NCI-2013-00740,0,-14.46054458618164,3.684521198272705,"Inclusion:

*Participants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration                                                                                                                         

*Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests                                                                   

* Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accrued              

Exclusion:                                                                  

Other clinically significant disorders such as:

* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; "
NCI-2013-00826,3,-11.966628074645996,1.8234076499938965,Human immunodeficiency virus (HIV)-positive patients will be eligible unless they have been previously diagnosed with an acquired immune deficiency syndrome (AIDS)-defining illness
NCI-2013-00858,0,9.483072280883789,-5.087620735168457,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-00877,0,8.689827919006348,-6.036988258361816,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-00890,4,6.4908647537231445,-5.5949201583862305,Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-00998,0,3.926807165145874,-2.4442086219787598,Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-01132,3,-0.03362293168902397,3.2398648262023926,"Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring protease inhibitor therapy, ... that would limit compliance with study requirements"
NCI-2013-01275,4,-6.826302528381348,-0.8821879029273987,"PHASE I: Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a cluster of differentiation 4 (CD4) count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded

PHASE II: HIV positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded"
NCI-2013-01320,3,-8.78115463256836,1.1372405290603638,Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
NCI-2013-01357,0,-1.0195063352584839,1.8546923398971558,"Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications

HIV-positive patients on combination antiretroviral therapy are ineligible"
NCI-2013-01368,0,5.682053565979004,5.079203128814697,"Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:

* CD4+ cells >= 350/mm^3 (nadir)

* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART

* No zidovudine or stavudine as part of cART

Patients who are HIV+ and do not meet all of these criteria are not eligible for this study"
NCI-2013-01452,0,9.03615665435791,-6.97554349899292,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-01474,0,4.741064548492432,-3.1414988040924072,"Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort

* HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4 

HIV-positive patients on combination antiretroviral therapy are ineligible"
NCI-2013-01491,4,-3.2974812984466553,3.955993890762329,"Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation (CD)4 count, not requiring antiretroviral medication will not be excluded"
NCI-2013-01496,0,8.74269962310791,-6.580472469329834,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-01520,0,-1.8896994590759277,4.455079078674316,"Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection"
NCI-2013-01568,0,9.805012702941895,-4.2158522605896,Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible
NCI-2013-01588,0,1.0953807830810547,-3.822650909423828,"TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible"
NCI-2013-01702,4,4.627441883087158,2.5630247592926025,"Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:

* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness

* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 

* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3

* Please note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4"
NCI-2013-01703,0,9.505545616149902,-6.715939044952393,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-01748,0,-8.873774528503418,1.177151083946228,"Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible"
NCI-2013-01850,4,-8.867142677307129,6.039931297302246,"Severe, active co-morbidity, defined as follows:

* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol"
NCI-2013-01999,0,-12.960973739624023,-1.4518826007843018,Human immunodeficiency virus (HIV)-positive patients
NCI-2013-02103,0,9.803853988647461,-5.424185276031494,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2013-02167,0,-6.987486839294434,0.8348279595375061,Patients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later date
NCI-2013-02229,0,-4.55076265335083,-3.431593418121338,"Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:

* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low

* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia

* Patient must have serum HIV viral load of < 200 copies/mm^3

* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy

* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or zidovudine.

* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine"
NCI-2013-02238,0,-2.7315969467163086,2.9660985469818115,"Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded"
NCI-2013-02288,3,-1.5920751094818115,-5.491657257080078,"EXCLUSION

Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair

Inclusion:

HIV-positive; documentation of HIV-1 infection by means of any one of the following: 

* Documentation of HIV diagnosis in the medical record by a licensed health care provider

* Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participantÃ¢â¬â¢s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participantÃ¢â¬â¢s name)

* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL

* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay

Cluster of differentiation (CD)4 count >= 200 within 120 days prior to enrollment or plasma HIV-1 RNA < 200 copies/mL within 120 days prior to randomization
"
NCI-2013-02426,0,2.896244525909424,-3.500131368637085,Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy are eligible for inclusion; the use of zidovudine is not allowed
NCI-2014-00115,4,-9.819293975830078,-2.448686361312866,"Patients unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczematoid skin disorders, or (d) immunocompromised individuals, such as those with human immunodeficiency virus (HIV)"
NCI-2014-00416,1,3.8453643321990967,-3.845745325088501,"Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)

HIV-positive patients on combination antiretroviral therapy are ineligible"
NCI-2014-00461,4,-2.3477628231048584,2.5383481979370117,"Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications"
NCI-2014-00615,4,6.306541442871094,6.208544731140137,Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible
NCI-2014-00620,0,9.076802253723145,-4.777502536773682,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-00627,0,-0.6353609561920166,9.746784210205078,"Patients with a known history of human immunodeficiency virus (HIV) seropositivity:

* Must have undetectable viral load using standard HIV assays in clinical practice

* Must have cluster of differentiation (CD)4 count >= 400/mcL

* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)

* Must not be newly diagnosed within 12 months prior to sub-study registration"
NCI-2014-00629,4,-7.626514911651611,-0.25311416387557983,patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
NCI-2014-00631,0,-6.631689071655273,-2.149610996246338,Patients with known human immunodeficiency virus (HIV) infection
NCI-2014-00634,0,-12.369169235229492,2.1035215854644775,"Human immunodeficiency virus (HIV)-positive patients on strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors are ineligible"
NCI-2014-00635,0,-8.873178482055664,6.032334804534912,"Severe, active co-morbidity, defined as follows:

* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol"
NCI-2014-00636,0,-1.5624181032180786,-5.485187530517578,"HIV positive; documentation of HIV-1 infection by means of any one of the following:

* Documentation of HIV diagnosis in the medical record by a licensed health care provider;

* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participantÃ¢â¬â¢s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participantÃ¢â¬â¢s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);

* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;

* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay

* NOTE: A Ã¢â¬ÅlicensedÃ¢â¬Â assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies"
NCI-2014-00643,4,-1.76029372215271,4.4517035484313965,Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
NCI-2014-00644,0,6.286388874053955,7.004376411437988,"Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:

* Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3

* History of acquired immune deficiency syndrome (AIDS) indicator conditions

* Anti-retroviral therapy with any potent CYP3A4 inhibitor"
NCI-2014-00686,0,-8.793679237365723,9.124261856079102,"Although they will not be considered formal eligibility (exclusion) criteria, physicians should recognize that the following may seriously increase the risk to the patient entering this protocol:

* Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient

"
NCI-2014-00688,0,9.160207748413086,-6.171656608581543,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-00702,3,8.7302885055542,1.9706971645355225,"Severe, active co-morbidity, defined as follows:


* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) 4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol

"
NCI-2014-00746,0,-12.258466720581055,-0.6456365585327148,Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3
NCI-2014-00816,3,9.9025239944458,-5.897880554199219,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-00849,4,8.730401992797852,1.97068452835083,"Severe, active co-morbidity, defined as follows:


* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol

"
NCI-2014-00907,1,8.527832984924316,-7.161431789398193,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-01043,1,9.9932279586792,-2.8000762462615967,Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded
NCI-2014-01047,0,7.502491474151611,0.8589096665382385,"Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:

* No history of acquired immune deficiency syndrome (AIDS)-defining conditions

* CD4 cells > 350 cells/mm^3

* If on antiretroviral agents, must not include zidovudine or stavudine

* Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART

* Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactions"
NCI-2014-01072,0,-9.268887519836426,6.069780349731445,"Severe, active co-morbidity, defined as follows:	

* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol

"
NCI-2014-01106,0,-1.0192553997039795,1.8539655208587646,"Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications

HIV-positive patients on combination antiretroviral therapy are ineligible"
NCI-2014-01107,0,-9.289804458618164,0.6497508883476257,"Patients with human immunodeficiency virus (HIV) will not be denied an opportunity to participate in this clinical trial, if they have adequate cluster of differentiation (CD)4 counts (> 250 CD4+ T lymphocytes/uL) and would be able to be maintained on an antiretroviral combination without pronounced effects on cytochrome (CYP)3A4, 2C9, or 2C19"
NCI-2014-01118,0,8.700074195861816,-9.487115859985352,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible"
NCI-2014-01222,0,-9.168031692504883,-1.5619994401931763,Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded
NCI-2014-01223,0,-7.006388187408447,0.7472519874572754,Patients known to be positive for human immunodeficiency virus (HIV) are not eligible
NCI-2014-01340,0,11.457839012145996,-4.876531600952148,Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
NCI-2014-01470,0,5.085649013519287,3.4651057720184326,"Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:

* Cluster of differentiation (CD)4 cells >= 500/uL

* Serum HIV viral load of < 25,000 IU/ml

* No current antiretroviral therapy

** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)"
NCI-2014-01696,0,-13.841974258422852,8.078914642333984,"Negative serology (antibody test) for the following infectious diseases:

* Human immunodeficiency virus (HIV) type 1 and 2

* Human T-cell leukemia virus (HTLV) type 1 and 2 (mandatory in United States [US] but optional in Canada and Europe)

* Hepatitis B surface antigen

* Hepatitis C antibody"
NCI-2014-01747,0,4.843106269836426,9.915264129638672,Individuals who are known to be human immunodeficiency virus (HIV) infected are eligible (note: HIV testing is not required for entry into the study)
NCI-2014-01754,0,-6.273995876312256,1.681368112564087,Human immunodeficiency virus (HIV) positive patients will be excluded with the exception of patients without CD4 depletion (i.e. above the institutional lower limit of normal) and who have no other acquired immune deficiency syndrome (AIDS)-related complications and who have Epstein-Barr virus (EBV) negative tumors; the number of patients in this category is expected to be very low and the principal investigator (PI) will decide their eligibility on a case by case basis
NCI-2014-01810,4,8.0680513381958,2.3602418899536133,"Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol"
NCI-2014-01927,0,7.557531833648682,-4.917511463165283,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-01984,0,5.45720100402832,9.190558433532715,"Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:

* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective

* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL

* They must not be receiving prophylactic therapy for an opportunistic infection"
NCI-2014-02020,0,7.636122226715088,-6.741166114807129,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-02056,0,-1.6845755577087402,-8.331123352050781,"EXCLUSION:
Patients who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable

Patients who are receiving any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents or investigational agents within 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational agents for hepatitis C

INCLUSION:
HIV positive; HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participantÃ¢â¬â¢s HIV status based on either: 1) approved diagnostic tests or 2) the referring physicianÃ¢â¬â¢s written record that HIV infected was documented, with supporting information on the subjectÃ¢â¬â¢s relevant medical history and/or current management of HIV infection"
NCI-2014-02167,0,-0.4489070773124695,7.734049320220947,Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by PCR is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul
NCI-2014-02197,2,7.59281063079834,-6.218438148498535,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-02267,0,4.002591609954834,-2.325627088546753,Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
NCI-2014-02379,0,10.10944652557373,-2.3404886722564697,"Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectable"
NCI-2014-02403,0,-5.350894927978516,-1.0935165882110596,Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) 
NCI-2014-02405,0,-2.542642593383789,9.52877426147461,Patients must not have a known history of human immunodeficiency virus (HIV) seropositive
NCI-2014-02424,0,0.3116873502731323,7.532573223114014,"In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)"
NCI-2014-02474,4,8.195731163024902,-5.5457234382629395,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2014-02672,0,13.741533279418945,-1.1885546445846558,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: 

* Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition

* Cluster of differentiation (CD)4 cell count >= 250

* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone

* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449"
NCI-2014-02674,1,-6.351295471191406,0.04743677377700806,Patients with human immunodeficiency virus (HIV) infection are ineligible
NCI-2015-00030,4,8.132569313049316,1.576782464981079,"Severe, active co-morbidity defined as follows:

* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol"
NCI-2015-00052,4,-0.6660029888153076,-8.443849563598633,"EXCLUSION:
Participants who refuse antiretroviral therapy for HIV, if HIV positive

INCLUSION:

Documentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection

* If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subjectÃ¢â¬â¢s HIV status

If participant is HIV positive, participants must be on a stable antiretroviral regimen for at least 12 weeks prior to study enrollment"
NCI-2015-00054,0,8.545612335205078,8.058368682861328,"Patients who are human immunodeficiency virus (HIV)-positive are eligible if: 

* CD4+ cell count greater or equal to 250 cells/mm^3

* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used

* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts

* Probable long-term survival with HIV if cancer were not present"
NCI-2015-00121,0,4.140968322753906,-4.662652015686035,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patientÃ¢â¬â¢s general health and cluster of differentiation (CD)4 counts are within acceptable levels"
NCI-2015-00127,0,8.741131782531738,-4.5537261962890625,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-00128,1,5.761647701263428,8.42281436920166,Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
NCI-2015-00130,0,-8.802570343017578,-2.1265010833740234,"EXCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C):  HIV-positive patients are eligible if the following criteria are met:

* Stable on their antiretroviral agents

* Have CD4 counts above 400

* Undetectable viral loads, and

* No need for prophylactic medications for an opportunistic infections 

EXCLUSION CRITERIA FOR DIPG (STRATUM A):  human immunodeficiency virus (HIV)-positive patients are eligible if the following criteria are met:

* Stable on their antiretroviral agents

* Have CD4 counts above 400

* Undetectable viral loads, and

* No need for prophylactic medications for an opportunistic infections

EXCLUSION CRITERIA FOR NB-NGG (STRATUM B): HIV-positive patients are eligible if the following criteria are met:

* Stable on their antiretroviral agents

* Have CD4 counts above 400

* Undetectable viral loads, and

* No need for prophylactic medications for an opportunistic infections"
NCI-2015-00159,0,-7.830265045166016,-0.4658493101596832,Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200
NCI-2015-00257,0,4.622838020324707,2.5182924270629883,"Human immunodeficiency virus (HIV)-infected persons are eligible if they meet other eligibility criteria including the following:

* No prior acquired immune deficiency syndrome (AIDS)-defining condition other than cluster of differentiation (CD)4+ cells nadir < 200/mm^3

* Pre-leukemia CD4+ cell count >= 250/mm^3

* Willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study; no zidovudine- and no ritonavir-containing regimens and no 3-drugs-in-1 pill regimens containing pharmacologic boosters are allowed; recommended regimens are integrase inhibitors combined with tenofovir and emtricitabine"
NCI-2015-00258,0,-12.898207664489746,-1.4022533893585205,Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
NCI-2015-00260,3,-1.4858176708221436,10.613897323608398,"No history of the following:

* Patients with human immunodeficiency virus (HIV) are eligible if the lymphocytes > 350 cluster of differentiation (CD)4+ cells and no detectable viral load

"
NCI-2015-00323,0,-13.776074409484863,7.793853282928467,"Human immunodeficiency (HIV) positive (+) patients are eligible provided they meet the other eligibility criteria and:

* Cluster of differentiation (CD)4+ cells are >= 250/mm^3

* There is no history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ cell count

* The following antiretroviral agents are not allowed: zidovudine, stavudine, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, combination pills with pharmacologic boosters

* Recommended antiretroviral regimens to avoid pharmacokinetic (PK) interactions include strand integrase inhibitors with nucleoside reverse transcriptase inhibitors (for example, dolutegravir given with tenofovir and emtricitabine)"
NCI-2015-00378,0,-7.124851703643799,0.20410773158073425,Patients with human immunodeficiency virus (HIV) are excluded
NCI-2015-00456,0,-7.7842936515808105,0.5608699917793274,"Uncontrolled intercurrent illness including, but not limited to: human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements; patients with HIV who have adequate CD4 counts and who have no requirement for antiviral therapy will be eligible"
NCI-2015-00461,0,-0.4932415783405304,-8.451244354248047,"HIV plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays (limit of detection: 75) within 4 weeks prior to registration

HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participantÃ¢â¬â¢s relevant medical history and/or current management of HIV infection

Participants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable KS despite HAART for greater than or equal to 3 months)

* For participants in the relapsed refractory HIV-cHL expansion cohort, participants must have histologically confirmed, relapsed/refractory (defined as relapsed/refractory to one or greater lines of therapy) HIV-associated classical Hodgkin lymphoma

Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment

Criteria for Solid Tumor Expansion and Lymphoma Cohorts:

for the relapsed refractory HIV-cHL cohort, participants with CD4 count >= 100/mm^3 are permitted"
NCI-2015-00547,0,4.002237796783447,-2.324880361557007,Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
NCI-2015-00606,4,-11.53749942779541,1.1327803134918213,Known human immunodeficiency virus (HIV)-positive individuals are ineligible
NCI-2015-00651,0,-11.537118911743164,1.1330840587615967,Known human immunodeficiency virus (HIV)-positive individuals are ineligible
NCI-2015-00668,0,14.22146987915039,0.2241339236497879,"Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:

* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma

* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma

* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed

* Zidovudine is not allowed

* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed

* Patients with multi-drug resistant HIV are not eligible"
NCI-2015-00695,0,-8.04060173034668,10.201794624328613,"Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to known human immunodeficiency virus (HIV) infection requiring protease inhibitor therapy, "
NCI-2015-00741,1,6.46828556060791,-6.145108699798584,Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; 
NCI-2015-00744,0,4.753678321838379,8.690289497375488,Immunocompromised patients (other than that related to the primary oncologic diagnosis or to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive are not eligible
NCI-2015-00835,4,5.391249179840088,-2.1773858070373535,"Patient does not have known human immunodeficiency virus syndrome (HIV, testing optional); known HIV-positive patients receiving combination antiretroviral therapy are ineligible"
NCI-2015-00866,4,4.817996501922607,9.263081550598145,Patients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the study
NCI-2015-01000,0,14.631772994995117,-0.38949915766716003,"Human immunodeficiency virus (HIV) infected patients (if HIV positive)

* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:

** No history of acquired immune deficiency syndrome (AIDS) defining illness other than an historic CD4+ T-cell nadir < 200/mm^3

** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:

*** The CD4+ T-cell counts were generally in excess of 300/mm^3

*** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy

*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms

*** Zidovudine is not allowed as part of the anti-HIV therapy"
NCI-2015-01053,0,8.862191200256348,-5.368299961090088,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-01097,0,8.489693641662598,-5.353104591369629,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-01098,3,2.5548908710479736,-0.9421522617340088,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated"
NCI-2015-01139,4,1.3121535778045654,1.248821496963501,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MLN0128 and AZD9291;  in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated"
NCI-2015-01270,4,3.525912284851074,-2.523505449295044,Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible
NCI-2015-01271,0,-2.7093818187713623,9.535369873046875,History of human immunodeficiency virus (HIV) infection
NCI-2015-01408,4,4.542730808258057,-1.739538311958313,Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible
NCI-2015-01411,0,8.204238891601562,-6.043484687805176,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-01548,0,8.501626968383789,2.0797009468078613,"Severe, active comorbidity, defined as follows:

* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter

** Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to Step 1 registration

** Note: HIV testing is not required for eligibility for this protocol"
NCI-2015-01640,0,15.027666091918945,-0.45622819662094116,"Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following: 

* No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)

* After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible

* At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3

* At the time of study entry the HIV viral load must be undetectable by standard laboratory assay 

* During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status

* No history of non-adherence to cART and willing to adhere to cART while on study

* Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:

** Efavirenz not allowed due to potential central nervous system (CNS) toxicity

** Stavudine not allowed due to potential neuropathic effects

** Zidovudine not allowed due to myelosuppressive effects

* Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management"
NCI-2015-01643,0,14.023112297058105,-0.6564533114433289,"Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible"
NCI-2015-01681,0,2.1546902656555176,-2.6498634815216064,"Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:

* CD4+ T-cells >= 250/mm^3

* HIV sensitive to antiretroviral therapy

* Zidovudine not allowed

* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma

* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma"
NCI-2015-01707,0,8.285099029541016,-4.510875225067139,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-01744,0,8.20988941192627,-8.914968490600586,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patientÃ¢â¬â¢s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal
NCI-2015-01745,0,-1.7608906030654907,-8.323854446411133,"INCLUSION:

HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection

Must be on a multi-drug anti-HIV regimen (excluding zidovudine [AZT, ZDV, Retrovir], or agents containing zidovudine [e.g., Combivir and Trizivir], and efavirenz [Sustiva], or agents containing efavirenz [e.g., Atripla]), and have an HIV-1 viral load < 50 copies/mL by reverse transcriptase-polymerase chain reaction (RT-PCR) at the time of study enrollment; participants on zidovudine ([AZT, ZDV, Retrovir]; including Combivir and Trizivir and efavirenz [Sustiva]; including Atripla) must switch to an alternative regimen without anticipated drug-drug interactions or myelosuppressive properties based on known viral resistance patterns and/or ART history, such as raltegravir and Truvada (emtricitabine and tenofovir) at least two weeks prior to the transplant

EXCLUSION:
Any history of HIV-1 associated encephalopathy"
NCI-2015-01779,0,8.156913757324219,-6.559962749481201,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2015-01906,0,4.021488189697266,1.4442380666732788,"Histologically or cytologically proven metastatic or locally advanced tumors for which no standard therapy exists, or where standard therapy has failed, or in patients otherwise ineligible for standard therapy, or for an indication that anti-programmed cell death protein 1 (PD-1) therapy has been shown to be effective in studies in HIV-uninfected participants; disease-specific criteria will be applied for certain common cancers and cancers strongly associated with HIV; however, enrollment will not be confined to these tumors

On an effective combination cART regimen, generally a 3-drug regimen based on Department of Health and Human Services (DHHS) treatment guidelines

* Patients must be on cART >= 4 weeks; and

* Evidence of viral suppression defined as HIV viral load < 200 copies/mL; and 

* Most patients have viral loads that are suppressible to < 50 copies/mL, but about 25% of patients will occasionally have blips up to 400Ã¢â¬â500 copies/mL, which do not appear to correlate with lack of viral suppression in most studies; thus, an HIV viral load of =< 400 copies/mL for an occasional Ã¢â¬ÅblipÃ¢â¬Â will be allowed, if there is documentation of an HIV viral load < 200 on the same regimen and no significant treatment interruption 

Total bilirubin < 1.5 X upper limit of normal (ULN); or < 3 x institutional ULN for GilbertÃ¢â¬â¢s syndrome or HIV protease inhibitors; or < 5 x ULN and direct bilirubin < 0.7 mg/dL for patients on atazanavir containing HIV regimen"
NCI-2015-01907,0,2.710261583328247,-4.558133125305176,"INCLUSION:

Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following:

* Cluster of differentiation (CD)4+ cell count >= 250/mm^3

* Not on antiretroviral therapy affecting cytochrome P450 (p450) metabolism

* HIV viral loads undetectable by standard clinical tests

EXCLUSION:

Known HIV-positive patients receiving combination antiretroviral therapy are ineligible; however, HIV testing is not required for study enrollment and optional"
NCI-2015-01910,0,2.9483895301818848,-1.6319928169250488,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
NCI-2015-01913,4,-1.2384669780731201,9.829143524169922,Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
NCI-2015-01915,4,14.015335083007812,-0.6557583212852478,"Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible"
NCI-2015-01916,0,-2.4952588081359863,7.694552421569824,"Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load"
NCI-2015-01917,4,0.47429507970809937,7.468659400939941,"Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:

* No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3

* No antiretroviral therapy with overlapping toxicity such as myelosuppression

* HIV viral loads below the limit of detection

* No history of highly active antiretroviral therapy (HAART)-resistant HIV"
NCI-2015-02125,4,2.949005126953125,-1.630487322807312,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
NCI-2015-02126,0,3.7782232761383057,9.10814380645752,"Patients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with 3 or more drug anti-retroviral regimen and virus load less than 50 copies/ml and CD4 count greater than 250 cells/ml, and no concurrent opportunistic infection or other malignancy"
NCI-2015-02250,4,-2.538992404937744,9.529409408569336,CLINICAL/LABORATORY CRITERIA: patients must not have a known history of human immunodeficiency virus (HIV) seropositivity
NCI-2016-00050,4,-2.1829447746276855,9.484715461730957,Patients must not have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
NCI-2016-00071,0,-13.08288860321045,3.5171825885772705,"EXCLUSION:

Participants receiving any medications or substances that have antiviral activity against KSHV or that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 19 (2C19) are ineligible; the following drugs are also prohibited:

Strong Inhibitors of CYP3A4:

* HIV: non-nucleoside reverse transcriptase inhibitors (delaviridine, nevirapine), protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir), cobicistat-boosted antiretrovirals (e.g., elvitegravir); NOTE: Clinical trials have demonstrated that there are no clinically significant drug-drug interactions between nelfinavir and the following antiretrovirals: efavirenz (strong CYP3A4 inhibitor), etravirine (strong CYP3A4 inhibitor); therefore, these antiretrovirals will not be excluded

INCLUSION:

Known human immunodeficiency virus (HIV)-1 infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site;

HIV seropositive participants must be on antiretroviral therapy (ART) with the following criteria:

* A complete ART regimen that does not include the study drug as one of a minimum of 3 active drugs, which may include an integrase inhibitor or efavirenz in combination with nucleoside reverse-transcriptase inhibitors (NRTIs)

* The ART regimen must not include protease inhibitor (PIs); participants must not have received a PI-based regimen for at least 4 weeks prior to enrollment

* Participants must either have an undetectable HIV plasma ribonucleic acid (RNA), or if plasma RNA detectable, must be on the same stable regimen for a minimum of 12 weeks prior to study enrollment

* No minimum cluster of differentiation (CD)4 count, but maximum HIV plasma RNA of 1,000 copies/mL


"
NCI-2016-00195,0,-9.222188949584961,-1.4162770509719849,"Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, hepatitis C

HIV-positive patients are excluded from the study"
NCI-2016-00203,1,-2.421929121017456,9.559640884399414,"Known history of human immunodeficiency virus (HIV),"
NCI-2016-00222,0,13.995989799499512,-0.7288264036178589,"Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:

* Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy

* Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and

* Have no evidence of opportunistic infections"
NCI-2016-00325,0,-2.881849765777588,-1.4081394672393799,Human immunodeficiency virus (HIV) infection
NCI-2016-00326,0,-2.8233792781829834,-1.4764784574508667,No known evidence of human immunodeficiency virus (HIV) infection
NCI-2016-00355,4,11.461649894714355,-4.87539529800415,Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
NCI-2016-00666,4,5.653780460357666,9.59742546081543,"Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy"
NCI-2016-00667,0,-9.205514907836914,7.34466028213501,"Severe, active co-morbidity defined as follows:

* Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the cisplatin and IMRT involved in this protocol may be significantly immunosuppressive; patients with known HIV, CD4 counts >= 250/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included

"
NCI-2016-00787,0,-11.474011421203613,2.2253055572509766,"Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibiotics"
NCI-2016-00843,0,-3.451470375061035,3.9430503845214844,"Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation 4 (CD4) count, not requiring antiretroviral medication, may be enrolled"
NCI-2016-00849,0,7.60947322845459,1.8654357194900513,"Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol"
NCI-2016-00963,0,7.618128776550293,1.9152374267578125,"Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 1 registration; note also that HIV testing is not required for eligibility for this protocol"
NCI-2016-01040,0,7.167022228240967,-3.6735680103302,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD4 count > 350 cells/mm^3 with an undetectable viral load
NCI-2016-01041,4,8.572312355041504,8.07407283782959,"Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:

1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3

2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used

3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts

4. Probable long-term survival with HIV if cancer were not present"
NCI-2016-01081,0,-6.855953693389893,-5.718941688537598,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01087,0,-8.66724967956543,1.0349602699279785,"Uncontrolled intercurrent illness including, but not limited to, o human immunodeficiency virus (HIV); patients with HIV who have adequate cluster of differentiation (CD)4 counts and who have no requirement for antiviral therapy will be eligible"
NCI-2016-01094,1,2.949573040008545,-1.6323529481887817,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
NCI-2016-01104,0,-7.588022232055664,-5.295137882232666,"Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01130,0,-8.175287246704102,-6.0682525634765625,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test"
NCI-2016-01232,4,-7.4731125831604,-5.728299140930176,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01300,3,-0.6819316744804382,9.763978958129883,"Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:

* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months

* They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts

* They have an undetectable viral load on standard assays"
NCI-2016-01301,0,-7.463667392730713,-5.932387828826904,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01325,0,-7.163184642791748,0.09387772530317307,Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
NCI-2016-01326,0,6.045000076293945,-0.33321473002433777,"Patients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible"
NCI-2016-01346,0,3.277111530303955,-0.8118183612823486,"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV-positive patients with undetectable viral loads and CD4 counts > 300, and not on any antiretroviral therapy may be allowed after discussing with the principal investigator"
NCI-2016-01356,0,9.808382987976074,-6.365049362182617,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2016-01363,0,7.5036420822143555,-5.3558430671691895,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2016-01364,0,9.243827819824219,-5.693778991699219,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2016-01403,3,6.535623550415039,-8.252355575561523,"Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:

* HIV is sensitive to antiretroviral therapy

* Must be willing to take effective antiretroviral therapy if indicated

* CD4 count at screening >= 300 cells/mm^3

* No history of acquired immune deficiency syndrome (AIDS)-defining conditions"
NCI-2016-01417,4,-7.651473045349121,-5.311057090759277,"Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01430,0,-7.465255260467529,-5.909822940826416,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2016-01461,0,-0.7925962209701538,4.526460647583008,"Other viral infections

* Known to have acute or chronic active hepatitis B or hepatitis C infection

* Known to have human immunodeficiency virus (HIV) infection

* Prior therapy with viral-based tumor vaccine

* Received live vaccine within 28 days prior to enrollment

individuals known to have HIV infection"
NCI-2016-01494,0,-6.7492828369140625,-2.124699354171753,Patients with known human immunodeficiency virus (HIV)
NCI-2016-01501,0,-0.7080979943275452,7.580848693847656,Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul; patients with a known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection might be enrolled if the viral load by PCR is undetectable with/without active treatment
NCI-2016-01595,0,-3.764802932739258,3.666963577270508,"Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:

* CD4 counts >= 350 mm^3

* Serum HIV viral load of < 25,000 IU/ml and

* Treated on a stable antiretroviral regimen"
NCI-2016-01597,0,-3.8240647315979004,5.035207271575928,"Patients must not have known human immunodeficiency virus (HIV), or a known positive test for hepatitis B virus surface antigen (HBV sAg), or hepatitis C virus ribonucleic acid (HCV antibody) indicating current acute or chronic infection; patients with a positive hepatitis C antibody with a negative viral load are allowed"
NCI-2016-01619,4,10.975132942199707,-8.124018669128418,"Major medical illnesses or psychiatric impairments, which in the investigators opinion, will prevent administration or completion of the protocol therapy and/or preclude informed consent; these include, but are not restricted to:

* HIV testing is not required for eligibility for this protocol, and known HIV positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 2 registration

"
NCI-2016-01698,4,-10.442689895629883,-1.9214602708816528,"Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV)"
NCI-2016-01733,0,3.2460153102874756,-2.5555102825164795,Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy that is a strong inducer CYP3A4; HIV-positive patient not on strong inducers of CYP3A4 are allowed
NCI-2016-01769,0,2.9496355056762695,-1.6304985284805298,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
NCI-2016-01771,0,8.73025131225586,1.9706017971038818,"Severe, active co-morbidity, defined as follows:

* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
"
NCI-2016-01804,4,-3.24422287940979,-0.8886967897415161,"Other viral infections:

* Known to have human immunodeficiency virus (HIV) infection

*individuals known to have HIV infection, 

"
NCI-2016-01844,0,-6.067435264587402,-0.06583311408758163," individuals known to have HIV infection are ineligible

Patients with other viral infections are ineligible:

* Known to have human immunodeficiency virus (HIV) infection"
NCI-2016-01847,0,7.585865020751953,-5.760473728179932,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
NCI-2016-01909,0,-11.782822608947754,1.9180948734283447,Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the study
NCI-2016-02009,3,6.512718677520752,5.936025142669678,"HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol"
NCI-2016-02060,4,9.587104797363281,-7.920209884643555,Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385
NCI-2017-00009,0,-4.551794052124023,-3.429290533065796," patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:

* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low

* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia* Patient must have serum HIV viral load of < 200 copies/mm^3

* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)

* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed due to potential pharmacokinetic interactions with leukemia

* Stavudine and zidovudine (AZT) are NOT allowed because of overlapping toxicity with protocol therapy"
NCI-2017-00105,0,-2.5692052841186523,10.442770004272461,Patients with a known history of human immunodeficiency virus (HIV) must have CD4 count >= institutional lower limit of normal within 28 days prior to registration
NCI-2017-00203,4,-9.610236167907715,5.9386515617370605,"Severe, active co-morbidity defined as follows:

* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol

"
NCI-2017-00712,1,-8.425209045410156,-5.854557037353516,"Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test"
NCI-2017-00766,2,-7.006707668304443,0.748638927936554,Patient who are known to be serologically positive for human immunodeficiency virus (HIV)
NCI-2017-01030,3,-7.465255260467529,-5.909822940826416,"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

* A stable regimen of highly active anti-retroviral therapy (HAART)

* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests"
NCI-2017-01425,3,5.8982672691345215,-0.3318561911582947," human immunodeficiency virus (HIV) (+) patients are eligible as long as they have: cd4 > 200, undetectable viral load and on highly active antiretroviral therapy (HAART) therapy"
